Horizon Discovery Group has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer for Horizon’s proprietary technologies to support the development and manufacture of a novel biomanufacturing cell line for commercial use.   Under the terms of the agreement, Horizon has licensed a novel cell line engineering technology to the Partner as well as non-exclusive rights to Horizon’s proprietary Helitron transposon gene editing technology fo...